News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Vladmir C. Cordeiro de Lima: Frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients
Vladmir C. Cordeiro de Lima/accamargo.org.br
Mar 4, 2025, 05:19

Vladmir C. Cordeiro de Lima: Frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients

Vladmir C. Cordeiro de Lima, Medical Oncologist at A C Camargo Cancer Center, shared an article by Erick F. Saldanha, et al. on X:

“Our paper describing the frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients is out at The Oncologist!

Mutation rate 2.8% (mostly never smokers). rwOS-25.9 mo.

Congratulatios to Erick Saldanha, Andres F. Cardona and all CLICaP!”

Real-world characteristics and outcomes of ERBB2-mutant NSCLC in Latin American patients (CLICaP).

Authors: Erick F. Saldanha, et al.

Vladmir C. Cordeiro de Lima: Frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients

A.C. Camargo Cancer Center Andres F. Cardona cancer CLICaP ERBB2 Erick Saldanha fight against cancer Global fight against cancer NSCLC OncoDaily Oncology The Oncologis Vladmir C. Cordeiro de Lima
Special Coverage
Science
Mar 4, 2025, 05:22
Rahul Banerjee: Teclistamab and Talquetamab are approved in Mexico for triple-class exposed
Science
Mar 4, 2025, 05:19
Vladmir C. Cordeiro de Lima: Frequency and characteristics of ERBB2 mutations in Latin American NSCLC patients
Blog
Mar 4, 2025, 05:18
Wafaa M Rashed: Access to medicine is just one piece of the puzzle
Blog
Mar 4, 2025, 04:58
Alba Fiorentino: The first Vision RT Ltd Italian User Meeting
Blog
Mar 4, 2025, 04:35
Razan Mohty: Outcomes of anti-CD19 CART for lymphoma in octogenarians
Blog
Mar 4, 2025, 04:35
Recommendations and best practices to boost vaccination and prevent HPV cancers - ECO
Science
Mar 3, 2025, 15:58
Esranur Aydın: Metastatic IDH2-mutant cholangiocarcinoma treated with venetoclax and decitabine
Science
Mar 3, 2025, 15:56
Selpercatinib in RET Fusion-Positive NSCLC by Oliver Gautschi et al.
Blog
Mar 3, 2025, 15:54
Jihan Azar: Childhood Cancer Inequalities in the WHO Eastern Mediterranean Region
Insight
Mar 3, 2025, 15:53
Arthur Sun Myint: Beacon of hope for patients with rectal cancer wishing to avoid major surgery and a stoma
Blog
Mar 3, 2025, 15:53
Toufic Kachaamy: Aasma Shaukat on how AI might accelerate precision medicine initiatives for CRC prevention
Blog
Mar 3, 2025, 15:52
Magdalena Skipper: An assault of science and scientists anywhere is an assault on science and scientists everywhere